RESEARCH PLATFORM FOR
THE MOON SHOTS PROGRAM
Immune checkpoint targeting is a new paradigm for cancer treatment. Rather than targeting the tumor cell, this approach targets molecules on immune cells that regulate their activity to sustain immune responses to cancer and achieve elimination of tumors and immunity to recurrence. This strategy has proven effective in treating many different types of cancer and is now the standard of care for metastatic melanoma. The immunotherapy platform provides MD Anderson investigators with support for immunotherapies in the treatment of a wide variety of tumor types and helps to link immunologic data with the genomic and proteomic platforms.
The platform has three components. The preclinical studies group
provides for animal studies to help establish feasibility and efficacy
of new treatments and combinations. The immunologic monitoring
component provides instrumentation and technical support for cellular
and molecular analysis of the impact of therapies on the immune system
in order to gain insight into mechanisms of action and to discover
biomarkers to identify patients who are likely to respond to or
develop adverse reactions to therapies. The immunopathology component
seeks to provide understanding of changes in the tumor
microenvironment associated with therapies.
Xổ số miền bắc thứ 4 hàng tuầnJames Allison, Ph.D.
Padmanee Sharma, M.D., Ph.D.
Xổ số miền bắc thứ 4 hàng tuầnProfessor, Genitourinary Medical Oncology
Xổ số miền bắc thứ 4 hàng tuần/content/mda/en/cancermoonshots/research_platforms/immunotherapy
News Release 10/01/2018Learn about his work
Jim Allison awarded Nobel Prize
Xổ số miền bắc thứ 4 hàng tuầnT cell discoveries led to game-changing treatment revolutionizing cancer care
Q&A: Understanding the Immunotherapy platform
Xổ số miền bắc thứ 4 hàng tuần"Our goal is to make immunotherapy a standard treatment option for many more types of cancers and patients."
Xổ số miền bắc thứ 4 hàng tuầnLearn how the team is impacting immunotherapy research and cancer care.
Expanding the reach of cancer immunotherapy
The National Institutes of Health (NIH) has selected MD Anderson as one of four national Cancer Immune Monitoring and Analysis Centers (CIMACs). The five-year, $210-million public-private partnership aims to identify and develop biomarkers to guide and improve treatments that help the immune system attack cancer. The Immunotherapy platform’s expertise in immune-monitoring was cited as one of the reasons MD Anderson was chosen to participate in this national initiative.